Evolving Challenges for Targeting Metabolic Abnormalities in Heart Failure

JACC: Heart Failure

Volumn 4, Issue 7, 2016, Pages 567-569

  Margulies, Kenneth B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diabetes; Metabolism; Myocardium; Remodeling

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; LIXISENATIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO;

CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DRUG MEGADOSE; EDITORIAL; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; CARDIAC MUSCLE; ENERGY METABOLISM; HEART; HEART VENTRICLE REMODELING;

ENERGY METABOLISM; HEART; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 84966680818     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.03.008     Document Type: Editorial

References (16)

1. Opie L.H. Metabolism of the heart in health and disease. I. Am Heart J 1968, 76:685-698.
2. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837-2842.
3. Davila-Roman V.G., Vedala G., Herrero P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002, 40:271-277.
4. Nikolaidis L.A., Sturzu A., Stolarski C., Elahi D., Shen Y.T., Shannon R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004, 61:297-306.
5. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005, 46:1019-1026.
6. Fields A.V., Patterson B., Karnik A.A., Shannon R.P. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol 2009, 32:236-243.
7. Bhashyam S., Fields A.V., Patterson B., et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010, 3:512-521.
8. Wei Y., Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996, 157:355-357.
9. Lepore J.J., Olson E., Demopoulos L., et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. J Am Coll Cardiol HF 2016, 4:559-566.
10. Marso S.P., Poulter N.R., Nissen S.E., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013, 166:823-830 e5.
11. Tucker ME. Top-line data show CV benefit for liraglutide in type 2 diabetes. Available at: . Accessed June 7, 2016. http://www.medscape.com/viewarticle/859905.
12. Pfeffer M.A., Claggett B., Diaz R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015, 373:2247-2257.
13. Margulies K.B., Anstrom K.J., Hernandez A.F., et al. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 2014, 7:673-679.
14. Margulies K.B., Anstrom K.J., Redfield M.M., et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction. Circulation 2015, 132:2267-2285.
15. Gilbert R.E., Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015, 385:2107-2117.
16. Wu S., Hopper I., Skiba M., Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Therap 2014, 32:147-158.